Targeting the right parameters in PAH remediation studies

Polycyclic aromatic hydrocarbon (PAH) occurrence and remediation methods

Polycyclic aromatic hydrocarbons (PAHs) are potentially mutagenic and carcinogenic substances occurring at various concentrations in atmosphere, soils, waters and sediments. PAHs, inherited both from natural and anthropogenic processes, are persistent organic pollutants (POP) due to their chemical stability and biodegradation resistance. The increase of road transportation, and of industrial an...

Targeting the Right Online Behaviors

Outcome Measure: Online interpersonal victimization (ie, unwanted sexual solicitation or harassment). Results: Aggressive behavior in the form of making rude or nasty comments (adjusted odds ratio [AOR], 2.3; P .001) or frequently embarrassing others (AOR, 4.6; P=.003), meeting people in multiple ways (AOR, 3.4; P .001), and talking about sex online with unknown people (AOR, 2.0; P=.02) were si...

Measuring the effects of treatment in patients with PAH: should we image the right ventricle?

Treatment for pulmonary arterial hypertension (PAH) has really only been available for the last 16 years. Progress has been extremely rapid, and both the mortality and the morbidity from this condition have been improved by the application of one or more of three groups of therapy, the endothelin receptor antagonists (ETRA), the agents promoting the nitric oxide pathway (both phosphodiesterase ...

PARP inhibitors: targeting the right patients.

‘Striking the Right Balance’ in Targeting PPARγ in the Metabolic Syndrome: Novel Insights from Human Genetic Studies

At a time when the twin epidemics of obesity and type 2 diabetes threaten to engulf even the most well-resourced Western healthcare systems, the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) has emerged as a bona fide therapeutic target for treating human metabolic disease. The novel insulin-sensitizing antidiabetic thiazolidinediones (TZDs, e.g., rosiglitazone, ...